Sanara MedTech (SMTI) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Sanara MedTech is set to release its Q2 2025 earnings on Wednesday, August 13th, with analysts predicting a loss of ($0.33) per share and revenue of $25.15 million.
• In its last quarterly earnings report, the company posted a loss of ($0.41) per share, falling short of estimates, and reported revenue of $23.43 million.
• HC Wainwright has increased its price target on the stock from $51.00 to $53.00, maintaining a "buy" rating for Sanara MedTech.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect Sanara MedTech to post earnings of ($0.33) per share and revenue of $25.15 million for the quarter.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The firm had revenue of $23.43 million for the quarter, compared to the consensus estimate of $23.48 million. Sanara MedTech had a negative return on equity of 29.22% and a negative net margin of 12.48%. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Price Performance

Shares of NASDAQ:SMTI traded up $0.44 during trading on Friday, reaching $24.80. The company had a trading volume of 37,206 shares, compared to its average volume of 47,803. The company has a fifty day moving average of $27.66 and a two-hundred day moving average of $30.78. The stock has a market capitalization of $220.47 million, a P/E ratio of -18.51 and a beta of 1.26. Sanara MedTech has a 12 month low of $23.53 and a 12 month high of $39.08. The company has a current ratio of 2.77, a quick ratio of 2.54 and a debt-to-equity ratio of 1.18.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on shares of Sanara MedTech from $51.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, May 15th.

Hedge Funds Weigh In On Sanara MedTech

A hedge fund recently raised its stake in Sanara MedTech stock. Rhumbline Advisers boosted its position in Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) by 14.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,714 shares of the company's stock after acquiring an additional 483 shares during the period. Rhumbline Advisers' holdings in Sanara MedTech were worth $115,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.